The following is a summary of "Portfolio Management Strategies for Growth and Impact in Cell and Gene" co-authored by Precision experts Ansul Mangal & John Khoury, originally published in MedCity News.
Opportunities for Growth and Impact in Cell and Gene
Cell and gene therapy is a dynamic field requiring astute strategic portfolio management for capitalizing on opportunities and driving growth. With an impressive $11.7 billion in investments in 2023 and all indictors pointing to accelerated market growth in the coming years, navigating this highly competitive sector requires informed portfolio management decisions.
The groundswell of investment in cell and gene is promising news for patient populations with conditions that have been historically unmet. However, success in bringing novel therapies to market relies on informed portfolio management decisions.
Our Precision for Medicine experts advise that while opportunity for investment is plentiful with more than 1,800 ongoing clinical trials, strategic portfolio assessments and management is critical to success.
Read more about how our experts advise navigating this highly competitive sector in "Portfolio Management Strategies for Growth and Impact in Cell and Gene", published in MedCity News. Subscription required.
